80 related articles for article (PubMed ID: 24704450)
1. EEN regulates the proliferation and survival of multiple myeloma cells by potentiating IGF-1 secretion.
Huang EW; Xue SJ; Li XY; Xu SW; Cheng JD; Zheng JX; Shi H; Lv GL; Li ZG; Li Y; Liu CH; Chen XH; Liu H; Li J; Liu C
Biochem Biophys Res Commun; 2014 May; 447(2):271-7. PubMed ID: 24704450
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of multiple myeloma cell proliferation by ginsenoside Rg3 via reduction in the secretion of IGF-1.
Li Y; Yang T; Li J; Hao HL; Wang SY; Yang J; Luo JM
Mol Med Rep; 2016 Sep; 14(3):2222-30. PubMed ID: 27430248
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.
Zhang H; Chen J; Zeng Z; Que W; Zhou L
Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
6. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
[TBL] [Abstract][Full Text] [Related]
7. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
8. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.
Tu Y; Gardner A; Lichtenstein A
Cancer Res; 2000 Dec; 60(23):6763-70. PubMed ID: 11118064
[TBL] [Abstract][Full Text] [Related]
9. Cytokine-induced apoptosis inhibitor 1 inhibits the growth and proliferation of multiple myeloma.
Wang X; Pan J; Li J
Mol Med Rep; 2015 Aug; 12(2):2056-62. PubMed ID: 25901506
[TBL] [Abstract][Full Text] [Related]
10. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
11. Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma.
Huo J; Xu S; Lin B; Chng WJ; Lam KP
Leukemia; 2013 Apr; 27(5):1165-71. PubMed ID: 23138182
[TBL] [Abstract][Full Text] [Related]
12. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
[TBL] [Abstract][Full Text] [Related]
13. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.
Gauduchon J; Gouilleux F; Maillard S; Marsaud V; Renoir JM; Sola B
Clin Cancer Res; 2005 Mar; 11(6):2345-54. PubMed ID: 15788686
[TBL] [Abstract][Full Text] [Related]
14. Pleiotropic effects of PI-3' kinase/Akt signaling in human hepatoma cell proliferation and drug-induced apoptosis.
Alexia C; Bras M; Fallot G; Vadrot N; Daniel F; Lasfer M; Tamouza H; Groyer A
Ann N Y Acad Sci; 2006 Dec; 1090():1-17. PubMed ID: 17384242
[TBL] [Abstract][Full Text] [Related]
15. Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226.
Freund GG; Kulas DT; Mooney RA
J Immunol; 1993 Aug; 151(4):1811-20. PubMed ID: 7688386
[TBL] [Abstract][Full Text] [Related]
16. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R
Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643
[TBL] [Abstract][Full Text] [Related]
17. Effect of zinc on regulation of insulin-like growth factor signaling in human androgen-independent prostate cancer cells.
Banudevi S; Senthilkumar K; Sharmila G; Arunkumar R; Vijayababu MR; Arunakaran J
Clin Chim Acta; 2010 Feb; 411(3-4):172-8. PubMed ID: 19913001
[TBL] [Abstract][Full Text] [Related]
18. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling.
Ravid D; Maor S; Werner H; Liscovitch M
Oncogene; 2005 Feb; 24(8):1338-47. PubMed ID: 15592498
[TBL] [Abstract][Full Text] [Related]
19. Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.
Liang SB; Yang XZ; Trieu Y; Li Z; Zive J; Leung-Hagesteijn C; Wei E; Zozulya S; Coss CC; Dalton JT; Fantus IG; Trudel S
Clin Cancer Res; 2011 Jul; 17(14):4693-704. PubMed ID: 21632854
[TBL] [Abstract][Full Text] [Related]
20. ERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation.
Parrales A; López E; Lee-Rivera I; López-Colomé AM
Cell Signal; 2013 Apr; 25(4):829-38. PubMed ID: 23291002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]